MSME (Udyam registered) Ministry of MSME
- Udyam number
- UDYAM-GJ-06-0000130
Market Cap
₹276 Cr
LYKALABS · NSE
Share Price
₹76.60
+0.46% today
Revenue
₹128 Cr
FY 2025-26 · -7.3% YoY
EBITDA
−₹3.49 Cr
Margin -2.7%
Net Profit
−₹10.04 Cr
FY 2025-26 · -225.7% YoY
Debt / Equity
0.44
Interest cover -27.9x
Authorised capital
₹59 Cr
Registered with MCA
Paid-up capital
₹36.15 Cr
Issued & subscribed
About Lyka Labs Limited
Data last updated:
Lyka Labs Limited is a public limited company based in Ankleshwar, Gujarat, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 29 December 1976 and has been in existence for over 50 years.
The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L24230GJ1976PLC008738. Its GSTIN is 24AAACL0820G1Z5 (Gujarat). The company holds 5 GST registrations, of which 3 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 500259 and NSE: LYKALABS.
The company has an authorised share capital of ₹59 Cr and a paid-up capital of ₹36.15 Cr. It was formerly known as Lyka Labs Private Limited and Lyka Laboratories Pvt Ltd. It is led by directors including Kunal Narendra Gandhi (Managing Director) and Prashant Godha.
Its last annual general meeting (AGM) was held on 01 August 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 4801/B & 4802/A GIDC Indutrail Estate, Ankleshwar, Gujarat, India – 393002.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹128.44 Cr, a decline of 7.3% compared to the previous year. For the same year it recorded a net loss of ₹10.04 Cr (net margin -7.8%) and EBITDA of -₹3.49 Cr (EBITDA margin -2.7%). The net worth stands at ₹92.39 Cr (down 12.7% YoY). Total assets are valued at ₹144.4 Cr (down 0.2% YoY).
The company has about 439 employees on its provident fund (EPFO) records. Its group structure includes 2 subsidiaries.
The company is associated with 1 brand: Lyka Labs. As per MCA filings, the company has open charges of ₹294.9 Cr and satisfied charges of ₹666.64 Cr on record. Court records list 249 cases involving the company, including 94 filed by the company and 155 filed against it; 55 cases are pending. The company has 153 deals on record (145 market trades, 3 funding rounds, 3 secondary share transfers), with disclosed funding of ₹120.13 Cr; the latest was in September 2024. Its 9 peer companies in the Pharma industry (API Manufacturers, Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 5 larger and 4 smaller; the largest is Alventa Pharma Limited with revenue of ₹142.72 Cr. The company has 34 MSME Form 1 returns on record between 2014 and 2024, listing 2,490 overdue payments to 126 micro and small suppliers.
Lyka Labs Limited is registered as an MSME under the Udyam registration framework (Reg. No. UDYAM-GJ-06-0000130). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website lykalabs.com.
Company details
CIN L24230GJ1976PLC008738
Registration Number 008738
Incorporation Date 29 December 1976
ROC Ahmedabad
Listing Status Listed - Listed on NSE (LYKALABS); Listed on BSE (500259)
Company Status Active
Date of Last AGM 01 August 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
MSME Classification MSME
Udyam Registration UDYAM-GJ-06-0000130
Name history
Lyka Labs has undergone 2 name changes throughout its history. The company was previously known as Lyka Labs Private Limited, and Lyka Laboratories Pvt Ltd. The current legal name is Lyka Labs Limited.
| Company Name | Status |
|---|---|
| Lyka Labs Limited | Current |
| Lyka Labs Private Limited | Previous |
| Lyka Laboratories Pvt Ltd | Previous |
Recognitions & Rankings of Lyka Labs
Contact details
Lyka Labs Limited's registered office is in Ankleshwar, Gujarat. Its website is lykalabs.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered Address4801/B & 4802/A GIDC Indutrail Estate, Ankleshwar, Gujarat, India – 393002
- IndustryPharma, Drug Formulation & Development, API Manufacturers
To see the full contact details of Lyka Labs Limited, buy the company report.
Comprehensive company report
Lyka Labs Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Lyka Labs operates one associated brand: Lyka Labs. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Pharmaceutical formulations and APIs are manufactured by Lyka Labs. | lykalabs.com |
Business activity
The main business activity of Lyka Labs is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Lyka Labs Limited, buy the company report.
Financials of Lyka Labs Limited
FY 2025-26 filings availableLyka Labs Limited reported revenue of ₹128.44 Cr (down 7.3% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue
₹128 Cr
-7.3% YoY
EBITDA
−₹3.49 Cr
-119.4% YoY
Profit After Tax
−₹10.04 Cr
-225.7% YoY
Net Worth
₹92.39 Cr
-12.7% YoY
Total Assets
₹144 Cr
-0.2% YoY
Total Debt
₹48.87 Cr
+28.0% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 128 | 138 | 111 | 93.07 | 194 | 86.25 | 61.49 |
| Revenue growth | -7.3% | +24.6% | +19.5% | -52.1% | +125.0% | +40.3% | - |
| EBITDA | (3.49) | 17.95 | 15.30 | 9.20 | 94.63 | 18.55 | (38.63) |
| EBITDA margin | -2.7% | +13.0% | +13.8% | +9.9% | +48.8% | +21.5% | -62.8% |
| Profit before tax | (11.78) | 11.14 | (0.94) | (13.17) | 59.24 | (14.15) | (61.87) |
| Net profit | (10.04) | 7.99 | (2.91) | (5.93) | 43.23 | (10.44) | (27.73) |
| Net profit margin | -7.8% | +5.8% | -2.6% | -6.4% | +22.3% | -12.1% | -45.1% |
| EPS (₹) | (2.81) | 2.24 | (0.75) | (4.30) | 13.59 | (4.03) | (21.10) |
| Balance sheet | |||||||
| Total assets | 144 | 145 | 130 | 124 | 150 | 152 | 149 |
| Net worth | 92.39 | 106 | 69.24 | 46.52 | 14.12 | (25.09) | (13.70) |
| Total debt | 48.87 | 38.17 | 57.70 | 74.03 | 130 | 163 | 141 |
| Cash & bank | 1.36 | 1.34 | 5.95 | 11.71 | 17.05 | 7.15 | 10.30 |
| Net working capital | 35.24 | 40.14 | 27.60 | 20.83 | 20.78 | (9.12) | (15.25) |
| Cash flow | |||||||
| Cash from operations | 5.24 | 1.90 | 1.77 | 8.95 | 79.25 | 8.81 | 5.32 |
| Cash from investing | (9.41) | (11.80) | (9.49) | 7.35 | (6.17) | (0.16) | (0.11) |
| Cash from financing | 4.19 | 5.29 | 1.95 | (21.64) | (63.18) | (11.80) | 3.38 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 42.31 | 28.03 | 30.73 | 36.66 | 33.03 | 33.43 | 33.80 | 41.16 |
| Revenue growth (YoY) | +28.1% | -16.2% | -9.1% | -10.9% | +9.7% | - | - | - |
| Other income | 0.42 | 0.61 | 1.16 | 1.09 | 0.63 | 0.82 | 0.83 | 0.03 |
| EBITDA | 4.55 | (6.45) | 1.65 | (2.54) | 3.69 | 4.08 | 5.20 | 4.96 |
| EBITDA margin | +10.8% | -23.0% | +5.4% | -6.9% | +11.2% | +12.2% | +15.4% | +12.1% |
| Depreciation | 2.01 | 2.04 | 2.15 | 2.15 | 2.11 | 1.42 | 1.83 | 1.76 |
| Interest | 1.01 | 0.70 | 0.82 | 0.79 | 0.85 | 0.47 | 0.61 | 0.54 |
| Profit before tax | 1.95 | (8.58) | (0.16) | (4.39) | 1.36 | 3.01 | 3.59 | 2.69 |
| Tax | (0.10) | (0.52) | (0.01) | (1.17) | 0.36 | 0.99 | 0.87 | 0.76 |
| Net profit | 2.05 | (8.06) | (0.15) | (3.22) | 1.00 | 2.02 | 2.72 | 1.93 |
| EPS (₹) | 0.57 | (2.10) | 0.00 | (0.94) | 0.25 | 0.49 | 0.75 | 0.58 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 121 | 135 | 106 | 80.59 | 164 | 62.26 | 40.74 |
| Revenue growth | -10.2% | +26.6% | +32.0% | -51.0% | +164.0% | +52.8% | - |
| EBITDA | (25.41) | 17.40 | 14.51 | 8.43 | 92.83 | 12.99 | (32.72) |
| EBITDA margin | -21.0% | +12.9% | +13.6% | +10.5% | +56.5% | +20.9% | -80.3% |
| Profit before tax | (33.23) | 11.09 | (0.93) | (13.21) | 60.24 | (18.40) | (55.16) |
| Net profit | (9.28) | 7.87 | (2.31) | (6.23) | 42.99 | (13.03) | (27.77) |
| Net profit margin | -7.7% | +5.8% | -2.2% | -7.7% | +26.2% | -20.9% | -68.2% |
| EPS (₹) | (9.05) | 2.22 | (0.69) | (4.33) | 13.91 | (5.04) | (19.31) |
| Balance sheet | |||||||
| Total assets | 141 | 163 | 161 | 154 | 178 | 179 | 177 |
| Net worth | 87.00 | 123 | 100 | 77.51 | 45.22 | 5.12 | 19.42 |
| Total debt | 48.87 | 38.17 | 57.70 | 73.02 | 128 | 162 | 136 |
| Cash & bank | 1.19 | 1.33 | 5.89 | 8.70 | 15.38 | 6.53 | 8.40 |
| Net working capital | 32.80 | 44.44 | 28.57 | 20.94 | 20.92 | (8.35) | (13.46) |
| Cash flow | |||||||
| Cash from operations | 5.09 | (1.62) | 3.09 | 6.87 | 76.53 | 5.75 | (11.45) |
| Cash from investing | (9.42) | (11.22) | (8.61) | 6.77 | (4.33) | 0.13 | 0.13 |
| Cash from financing | 4.19 | 8.25 | 2.71 | (20.33) | (63.35) | (7.75) | 19.61 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 42.31 | 28.03 | 30.73 | 32.97 | 29.18 | 30.52 | 32.92 | 41.16 |
| Revenue growth (YoY) | +45.0% | -8.2% | -6.7% | -19.9% | -3.1% | - | - | - |
| Other income | 0.42 | 0.51 | 1.37 | 1.21 | 0.77 | 0.82 | 0.87 | 0.13 |
| Total expenses | 37.72 | 55.53 | 28.83 | 36.12 | 25.82 | 27.22 | 27.84 | 35.82 |
| EBITDA | 4.59 | (27.50) | 1.90 | (3.15) | 3.36 | 3.30 | 5.08 | 5.34 |
| EBITDA margin | +10.8% | -98.1% | +6.2% | -9.6% | +11.5% | +10.8% | +15.4% | +13.0% |
| Depreciation | 2.01 | 2.04 | 2.15 | 2.07 | 2.11 | 1.42 | 1.75 | 1.68 |
| Interest | 1.01 | 0.87 | 0.82 | 0.79 | 0.85 | 0.52 | 0.62 | 0.52 |
| Profit before tax | 1.99 | (29.90) | 0.30 | (4.80) | 1.17 | 2.18 | 3.58 | 3.27 |
| Tax | (0.11) | (0.13) | 0.00 | (1.17) | 0.36 | 0.96 | 0.89 | 0.79 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 30 Oct 2026
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 42.31 | 28.03 | 30.73 | 36.66 | 33.03 | 33.43 | 33.80 | 41.16 |
| Revenue growth (YoY) | +28.1% | -16.2% | -9.1% | -10.9% | +9.7% | - | - | - |
| Other income | 0.42 | 0.61 | 1.16 | 1.09 | 0.63 | 0.82 | 0.83 | 0.03 |
| EBITDA | 4.55 | (6.45) | 1.65 | (2.54) | 3.69 | 4.08 | 5.20 | 4.96 |
| EBITDA margin | +10.8% | -23.0% | +5.4% | -6.9% | +11.2% | +12.2% | +15.4% | +12.1% |
| Depreciation | 2.01 | 2.04 | 2.15 | 2.15 | 2.11 | 1.42 | 1.83 | 1.76 |
| Interest | 1.01 | 0.70 | 0.82 | 0.79 | 0.85 | 0.47 | 0.61 | 0.54 |
| Profit before tax | 1.95 | (8.58) | (0.16) | (4.39) | 1.36 | 3.01 | 3.59 | 2.69 |
| Tax | (0.10) | (0.52) | (0.01) | (1.17) | 0.36 | 0.99 | 0.87 | 0.76 |
| Net profit | 2.05 | (8.06) | (0.15) | (3.22) | 1.00 | 2.02 | 2.72 | 1.93 |
| EPS (₹) | 0.57 | (2.10) | 0.00 | (0.94) | 0.25 | 0.49 | 0.75 | 0.58 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 128 | 138 | 111 | 93.07 | 194 | 86.25 | 61.49 |
| Revenue growth | -7.3% | +24.6% | +19.5% | -52.1% | +125.0% | +40.3% | - |
| Other income | 3.50 | 2.23 | 1.45 | 3.65 | 2.09 | 1.56 | 4.84 |
| Total expenses | 132 | 121 | 95.89 | 83.87 | 99.45 | 67.70 | 100 |
| Employee cost | 41.85 | 34.63 | 26.77 | 18.61 | 18.06 | 14.57 | 13.86 |
| EBITDA | (3.49) | 17.95 | 15.30 | 9.20 | 94.63 | 18.55 | (38.63) |
| EBITDA margin | -2.7% | +13.0% | +13.8% | +9.9% | +48.8% | +21.5% | -62.8% |
| Depreciation | 8.46 | 6.77 | 12.80 | 14.15 | 17.35 | 8.32 | 8.01 |
| Interest | 3.33 | 2.27 | 4.89 | 11.87 | 20.13 | 25.94 | 20.07 |
| Profit before tax | (11.78) | 11.14 | (0.94) | (13.17) | 59.24 | (14.15) | (61.87) |
| Tax | (1.34) | 3.20 | 1.69 | (0.02) | 20.80 | (4.06) | 0.75 |
| Net profit | (10.04) | 7.99 | (2.91) | (5.93) | 43.23 | (10.44) | (27.73) |
| Net profit margin | -7.8% | +5.8% | -2.6% | -6.4% | +22.3% | -12.1% | -45.1% |
| EPS (₹) | (2.81) | 2.24 | (0.75) | (4.30) | 13.59 | (4.03) | (21.10) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 35.69 | 36.77 | 34.17 | 31.77 | 29.47 | 29.40 | 29.33 |
| Reserves & surplus | 56.70 | 69.05 | 26.00 | (2.69) | (15.35) | (54.49) | (43.03) |
| Shareholders' funds (net worth) | 92.39 | 106 | 69.24 | 46.52 | 14.12 | (25.09) | (13.70) |
| Minority interest | (1.56) | (1.16) | 0.11 | 0.23 | 0.15 | 0.70 | (0.77) |
| Secured loans | 31.36 | 23.01 | 19.47 | 4.01 | 5.17 | 152 | 131 |
| Unsecured loans | 17.51 | 15.16 | 38.23 | 70.02 | 124 | 10.68 | 9.77 |
| Total debt | 48.87 | 38.17 | 57.70 | 74.03 | 130 | 163 | 141 |
| Total liabilities | 144 | 145 | 130 | 124 | 150 | 152 | 149 |
| Assets | |||||||
| Gross block | 202 | 191 | 160 | 158 | 177 | 202 | 188 |
| Net block | 87.11 | 85.11 | 57.70 | 68.09 | 93.95 | 98.19 | 105 |
| Capital work in progress | 1.88 | 1.20 | 23.05 | 16.23 | 17.74 | 25.76 | 27.76 |
| Investments | 0.03 | 0.04 | 0.09 | 0.05 | 0.02 | 0.02 | 0.02 |
| Inventories | 13.63 | 12.47 | 9.57 | 6.95 | 8.20 | 4.31 | 6.73 |
| Sundry debtors | 35.03 | 43.08 | 26.99 | 20.13 | 18.45 | 8.67 | 8.04 |
| Cash & bank balances | 1.36 | 1.34 | 5.95 | 11.71 | 17.05 | 7.15 | 10.30 |
| Loans & advances | 13.23 | 10.52 | 8.12 | 5.40 | 8.49 | 8.94 | 10.79 |
| Total current assets | 63.25 | 67.41 | 50.63 | 44.19 | 52.19 | 29.07 | 35.86 |
| Total current liabilities | 28.01 | 27.27 | 23.03 | 23.36 | 31.41 | 38.19 | 51.11 |
| Net working capital | 35.24 | 40.14 | 27.60 | 20.83 | 20.78 | (9.12) | (15.25) |
| Total assets | 144 | 145 | 130 | 124 | 150 | 152 | 149 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 1.34 | 5.95 | 11.71 | 17.05 | 7.15 | 10.30 | 1.71 |
| Net cash from operating activities | 5.24 | 1.90 | 1.77 | 8.95 | 79.25 | 8.81 | 5.32 |
| Net cash from investing activities | (9.41) | (11.80) | (9.49) | 7.35 | (6.17) | (0.16) | (0.11) |
| Net cash from financing activities | 4.19 | 5.29 | 1.95 | (21.64) | (63.18) | (11.80) | 3.38 |
| Net change in cash | 0.02 | (4.60) | (5.76) | (5.34) | 9.90 | (3.15) | 8.60 |
| Closing cash | 1.36 | 1.34 | 5.95 | 11.71 | 17.05 | 7.15 | 10.30 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -7.3% | +24.6% | +19.5% | -52.1% | +125.0% | +40.3% | - |
| EBITDA growth | -119.4% | +17.3% | +66.3% | -90.3% | +410.1% | +148.0% | - |
| PBT growth | - | +9998.0% | +92.9% | - | +9998.0% | +77.1% | -300.7% |
| Net income growth | -225.7% | +374.6% | +50.9% | -113.7% | +514.1% | +62.4% | - |
| Revenue CAGR (3Y) | +11.3% | -10.6% | +8.8% | +14.8% | +40.0% | +13.0% | -17.6% |
| EBITDA CAGR (3Y) | - | -42.5% | -6.2% | - | - | - | - |
| Profitability & leverage | |||||||
| Net income margin | -8.1% | +5.7% | -2.4% | -14.1% | +19.8% | -11.7% | -101.8% |
| Return on capital employed | 0.0% | +6.6% | 0.0% | 0.0% | +40.6% | 0.0% | 0.0% |
| Return on net worth | 0.0% | +5.3% | 0.0% | 0.0% | +77.6% | 0.0% | 0.0% |
| Debt / equity | 0.44 | 0.55 | 1.14 | 3.36 | 0.00 | 0.00 | 7.82 |
| Long-term debt / equity | 0.21 | 0.35 | 0.93 | 2.09 | 0.00 | 0.00 | 6.75 |
| Interest cover | -27.87 | 20.30 | 195.60 | -239.80 | 26.05 | 253.57 | -43.03 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.65 | 0.79 | 0.70 | 0.56 | 1.02 | 0.44 | 0.31 |
| Inventory turnover | 9.84 | 12.57 | 13.46 | 12.29 | 31.03 | 15.63 | 8.96 |
| Debtors turnover | 3.29 | 3.95 | 4.72 | 4.82 | 14.31 | 10.32 | 5.42 |
| EPS (₹) | (2.81) | 2.24 | (0.75) | (4.30) | 13.59 | (4.03) | (21.10) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 25.89 | 29.35 | 17.86 | 9.12 | 4.65 | (8.99) | (5.00) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 42.31 | 28.03 | 30.73 | 32.97 | 29.18 | 30.52 | 32.92 | 41.16 |
| Revenue growth (YoY) | +45.0% | -8.2% | -6.7% | -19.9% | -3.1% | - | - | - |
| Other income | 0.42 | 0.51 | 1.37 | 1.21 | 0.77 | 0.82 | 0.87 | 0.13 |
| Total expenses | 37.72 | 55.53 | 28.83 | 36.12 | 25.82 | 27.22 | 27.84 | 35.82 |
| EBITDA | 4.59 | (27.50) | 1.90 | (3.15) | 3.36 | 3.30 | 5.08 | 5.34 |
| EBITDA margin | +10.8% | -98.1% | +6.2% | -9.6% | +11.5% | +10.8% | +15.4% | +13.0% |
| Depreciation | 2.01 | 2.04 | 2.15 | 2.07 | 2.11 | 1.42 | 1.75 | 1.68 |
| Interest | 1.01 | 0.87 | 0.82 | 0.79 | 0.85 | 0.52 | 0.62 | 0.52 |
| Profit before tax | 1.99 | (29.90) | 0.30 | (4.80) | 1.17 | 2.18 | 3.58 | 3.27 |
| Tax | (0.11) | (0.13) | 0.00 | (1.17) | 0.36 | 0.96 | 0.89 | 0.79 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 121 | 135 | 106 | 80.59 | 164 | 62.26 | 40.74 |
| Revenue growth | -10.2% | +26.6% | +32.0% | -51.0% | +164.0% | +52.8% | - |
| Other income | 3.97 | 2.76 | 1.65 | 3.45 | 2.72 | 2.21 | 4.34 |
| Total expenses | 146 | 117 | 91.89 | 72.16 | 71.52 | 49.27 | 73.46 |
| Employee cost | 41.60 | 34.40 | 26.01 | 17.48 | 16.22 | 13.03 | 11.71 |
| EBITDA | (25.41) | 17.40 | 14.51 | 8.43 | 92.83 | 12.99 | (32.72) |
| EBITDA margin | -21.0% | +12.9% | +13.6% | +10.5% | +56.5% | +20.9% | -80.3% |
| Depreciation | 8.46 | 6.77 | 12.29 | 13.52 | 15.39 | 8.05 | 7.77 |
| Interest | 3.33 | 2.30 | 4.80 | 11.57 | 19.92 | 25.55 | 19.01 |
| Profit before tax | (33.23) | 11.09 | (0.93) | (13.21) | 60.24 | (18.40) | (55.16) |
| Tax | (0.94) | 3.19 | 1.34 | 0.08 | 20.34 | (3.94) | 0.24 |
| Net profit | (9.28) | 7.87 | (2.31) | (6.23) | 42.99 | (13.03) | (27.77) |
| Net profit margin | -7.7% | +5.8% | -2.2% | -7.7% | +26.2% | -20.9% | -68.2% |
| EPS (₹) | (9.05) | 2.22 | (0.69) | (4.33) | 13.91 | (5.04) | (19.31) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 35.69 | 36.77 | 34.17 | 31.77 | 29.47 | 29.40 | 29.33 |
| Reserves & surplus | 51.31 | 85.91 | 57.17 | 28.30 | 15.75 | (24.28) | (9.91) |
| Shareholders' funds (net worth) | 87.00 | 123 | 100 | 77.51 | 45.22 | 5.12 | 19.42 |
| Secured loans | 32.73 | 23.01 | 19.47 | 3.34 | 3.78 | 151 | 127 |
| Unsecured loans | 16.14 | 15.16 | 38.23 | 69.68 | 124 | 10.58 | 9.35 |
| Total debt | 48.87 | 38.17 | 57.70 | 73.02 | 128 | 162 | 136 |
| Total liabilities | 141 | 163 | 161 | 154 | 178 | 179 | 177 |
| Assets | |||||||
| Gross block | 201 | 191 | 153 | 154 | 172 | 163 | 141 |
| Net block | 87.11 | 85.12 | 55.65 | 65.52 | 90.12 | 95.34 | 102 |
| Capital work in progress | 1.88 | 1.20 | 23.05 | 16.23 | 17.74 | 24.40 | 26.40 |
| Investments | 0.03 | 14.73 | 32.42 | 32.41 | 32.41 | 32.41 | 32.41 |
| Inventories | 13.63 | 12.47 | 9.56 | 6.94 | 8.18 | 4.30 | 5.71 |
| Sundry debtors | 32.91 | 40.45 | 25.73 | 17.16 | 17.59 | 9.90 | 6.59 |
| Cash & bank balances | 1.19 | 1.33 | 5.89 | 8.70 | 15.38 | 6.53 | 8.40 |
| Loans & advances | 12.69 | 15.89 | 8.68 | 9.49 | 6.03 | 5.00 | 9.99 |
| Total current assets | 60.42 | 70.14 | 49.86 | 42.29 | 47.18 | 25.73 | 30.69 |
| Total current liabilities | 27.62 | 25.70 | 21.29 | 21.35 | 26.26 | 34.08 | 44.15 |
| Net working capital | 32.80 | 44.44 | 28.57 | 20.94 | 20.92 | (8.35) | (13.46) |
| Total assets | 141 | 163 | 161 | 154 | 178 | 179 | 177 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 1.33 | 5.91 | 8.70 | 15.38 | 6.53 | 8.40 | 0.12 |
| Net cash from operating activities | 5.09 | (1.62) | 3.09 | 6.87 | 76.53 | 5.75 | (11.45) |
| Net cash from investing activities | (9.42) | (11.22) | (8.61) | 6.77 | (4.33) | 0.13 | 0.13 |
| Net cash from financing activities | 4.19 | 8.25 | 2.71 | (20.33) | (63.35) | (7.75) | 19.61 |
| Net change in cash | (0.14) | (4.59) | (2.81) | (6.69) | 8.85 | (1.88) | 8.28 |
| Closing cash | 1.19 | 1.33 | 5.89 | 8.70 | 15.38 | 6.53 | 8.40 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -10.2% | +26.6% | +32.0% | -51.0% | +164.0% | +52.8% | - |
| EBITDA growth | -246.0% | +19.9% | +72.1% | -90.9% | +614.6% | +139.7% | - |
| PBT growth | - | +9998.0% | +93.0% | - | +9998.0% | +66.6% | -678.0% |
| Net income growth | -217.9% | +440.7% | +62.9% | -114.5% | +429.9% | +53.1% | - |
| Revenue CAGR (3Y) | +14.5% | -6.4% | +19.6% | +25.5% | +58.6% | +14.3% | -19.5% |
| EBITDA CAGR (3Y) | - | -42.8% | +3.8% | - | +470.5% | - | - |
| Profitability & leverage | |||||||
| Net income margin | -26.7% | +5.9% | -2.1% | -16.5% | +24.3% | -23.2% | -136.0% |
| Return on capital employed | 0.0% | +6.2% | 0.0% | 0.0% | +36.0% | 0.0% | 0.0% |
| Return on net worth | 0.0% | +4.8% | 0.0% | 0.0% | +58.3% | 0.0% | 0.0% |
| Debt / equity | 0.42 | 0.43 | 0.73 | 1.64 | 5.77 | 12.15 | 1.91 |
| Long-term debt / equity | 0.20 | 0.28 | 0.60 | 1.02 | 4.20 | 11.23 | 1.71 |
| Interest cover | -9.83 | 21.64 | 216.22 | -227.31 | 25.72 | 517.21 | -46.95 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.62 | 0.78 | 0.69 | 0.50 | 0.98 | 0.41 | 0.35 |
| Inventory turnover | 9.27 | 12.23 | 12.90 | 10.66 | 26.34 | 12.44 | 6.99 |
| Debtors turnover | 3.30 | 4.07 | 4.96 | 4.64 | 11.96 | 7.55 | 2.25 |
| EPS (₹) | (9.05) | 2.22 | (0.69) | (4.33) | 13.91 | (5.04) | (19.31) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 24.38 | 34.07 | 27.28 | 19.22 | 15.49 | 1.54 | 6.55 |
To see the full year-wise statements and ratios of Lyka Labs Limited, buy the company report.
Board of directors of Lyka Labs Limited
Lyka Labs has 7 current directors and 24 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Prashant Godha | Director | 08 Aug 2022 | 4 Years 2 Months | Current |
| Babu Lal Jain Also directs: Vipra Closures Private Limited | Director | 08 Aug 2022 | 4 Years 2 Months | Current |
| Shashil Philip Mendonsa | Director | 08 Aug 2022 | 4 Years 2 Months | Current |
| Kunal Narendra Gandhi Also directs: Relic Technologies Limited, Hiralaxmi Multitrade Private Limited, Enai Trading and Investment Private Limited and 1 more | Managing Director | 12 Feb 2019 | 7 Years 8 Months | Current |
| Yogesh Babulal Shah Also directs: Hiralaxmi Multitrade Private Limited, Lyka Exports Limited | Director | 12 Feb 2020 | 6 Years 8 Months | Current |
| Archana Surendra Yadav Also directs: Systematic Industries Limited, J. Kumar Infraprojects Limited, V2 Retail Limited and 1 more | Director | 26 May 2025 | 1 Years 5 Months | Current |
Showing 6 of 7 current directors. View all directors
Peer comparison
Lyka Labs Limited is compared with the 9 companies closest to it by revenue in the Pharma industry (API Manufacturers, Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Alventa Pharma Limited | ₹142.72 Cr (FY 2025) | 82.0% | Kolkata, West Bengal, India | |||
| Apotex Pharmachem India Private Limited | ₹142.14 Cr (FY 2024) | -19.0% | Bangalore, Karnataka, India | |||
| Sovereign Pharma Private Limited | ₹142.09 Cr (FY 2025) | 15.0% | Mumbai, Maharashtra, India | |||
| Svizera Labs Private Limited | ₹142.05 Cr (FY 2022) | 7.0% | Thane, Maharashtra, India | |||
| Ratnatris Pharmaceuticals Private Limited | ₹141.71 Cr (FY 2025) | 35.0% | Ahmedabad, Gujarat, India | |||
| Azico Biophore India Private Limited | ₹140.48 Cr (FY 2024) | 25.0% | Hyderabad, Telangana, India | |||
| Aglowmed Limited | ₹139.55 Cr (FY 2025) | 11.0% | Patna, Bihar, India | |||
| Jackson Laboratories Private Limited | ₹139.35 Cr (FY 2024) | 14.0% | Punjab, India | |||
| Silicon Life Sciences Private Limited | ₹139.2 Cr (FY 2020) | 31.0% | Hyderabad, Telangana, India | |||
| Lyka Labs Limitedthis company | ₹128.44 Cr (FY 2026) | -₹10.04 Cr | -7.8% | -7.3% | 439 | Ankleshwar, Gujarat, India |
To see the full peer comparison of Lyka Labs Limited, buy the company report.
Auditor
Lyka Labs Limited is audited by D. Kothary & Co for the financial year 2025.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| D. Kothary & Co | FY 2025 | 105335W |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 58.40%, foreign institutional investors hold 0.20%, domestic institutional investors hold 0.60% and retail and other public shareholders hold 40.80%.
Sep 2026
QUARTER
58.40% Promoters
0.60% DII (Domestic Institutional)
0.20% FII (Foreign Institutional)
40.80% Retail & Others
Promoter holding - history
Now 58.40% · Sep 2026High 58.40% · Sep 2026Low 58.20% · Dec 2025
Shareholding trend - last 6 quarters
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 58.40% | 58.20% | 58.20% | 58.20% |
| Public | 41.60% | 41.80% | 41.80% | 41.80% |
Charges & borrowings
Open charges
₹294.9 Cr
Satisfied charges
₹666.64 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 16 Dec 2025 | 101214171 | Others | ₹1 Cr | Open | |
| 24 Jul 2023 | 100756852 | Yes Bank Limited | ₹36.38 Cr | Open | |
| 05 Feb 2011 | 10268383 | The Kapol Co-Operative Bank Ltd. | ₹7.65 Cr | Open | |
| 09 Feb 2009 | 10148364 | Dena Bank | ₹1.57 Cr | Open | |
| 01 Jun 2006 | 10007240 | Dena Bank | ₹3 Cr | Open |
To see the full charge records of Lyka Labs Limited, buy the company report.
Total charge records: 77 View all charges
Deals & funding
Lyka Labs Limited has 153 deals on record (145 market trades, 3 funding rounds, 3 secondary share transfers), with disclosed funding of ₹120.13 Cr; the latest was in September 2024.
Total deals
153
Market trades
145
Funding rounds
3
Secondary share transfers
3
Acquisitions
2
Disclosed funding
₹120.13 Cr
Deals on record (5 of 153)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Sep 2024 | Market trade | ₹3.26 Cr | Buyer: Graviton Research Capital LLP Seller: Graviton Research Capital LLP |
| Aug 2024 | Market trade | ₹2.82 Cr | Buyer: Graviton Research Capital LLP Seller: Graviton Research Capital LLP |
| Aug 2024 | Market trade | ₹6.53 Cr | Buyer: Multiplier Share and Stock Advisors Private Limited , NK Securities Research Private Limited Seller: Multiplier Share and Stock Advisors Private Limited , NK Securities Research Private Limited |
| Jan 2023 | Funding round | ₹97.65 Cr | Investors: Ipca Laboratories Limited |
| Aug 2022 | Market trade | ₹2.21 Cr | Buyer: XTX Markets LLP Seller: XTX Markets LLP |
To see the full deal history of Lyka Labs Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Lyka Labs Limited has 249 court cases on record: 94 filed by Lyka Labs, 155 filed against it. 55 cases are pending and 194 are disposed.
Total cases
249
Filed by the company
94
Filed against the company
155
Pending
55
Disposed
194
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 137 | 115 | 25 |
| High courts | 77 | 28 | 24 |
| NCLAT | 22 | 7 | 3 |
| NCLT | 10 | 4 | 2 |
| Supreme Court | 3 | 1 | 1 |
Cases on record (5 of 249)
| Court | Type of case | Party | Status |
|---|---|---|---|
| Supreme Court | Appeal | Filed against the company by Modi Lifecare Industries Ltd | Pending |
| NCLAT, NCLAT New Delhi | Interim or miscellaneous application | Filed against the company by Modi Lifecare Industries Limited | Pending |
| NCLAT, NCLAT New Delhi | Interim or miscellaneous application | Filed by the company against Modi Lifecare Industries Limited | Disposed |
| High Court | Court case (CARAP) | Filed by the company against Scutonix Lifesciences Private Limited and 3 others | Disposed |
| High Court | Court case (CARBP) | Filed by the company against Scutonix Life Sciences Pvt Ltd and 3 others | Disposed |
To see the full case history of Lyka Labs Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Lyka Labs Limited has 34 MSME Form 1 returns on record between 2014 and 2024, listing 2,490 overdue payments to 126 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 126)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| Protech Telelinks | |||
| Laqshya Logistics | |||
| an individual supplier | |||
| an individual supplier |
To see the full MSME payment records of Lyka Labs Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
Lyka Labs has 2 subsidiary companies. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.
2
Subsidiary companies
Key subsidiaries
| Company Name | CIN | Shares held |
|---|---|---|
| Yka BDR International Limited | U24234MH1993PLC072947 | |
| Lyka Exports Limited | U51100GJ1992PLC023975 |
To see the full group structure of Lyka Labs Limited, buy the company report.
Employees & EPFO
Lyka Labs Limited has a workforce of 439 employees on its EPFO records as of Oct 08, 2025, across 2 active EPFO establishments.
Employee count
439
Active EPFO establishments
2
Employee growth
25.07%
GST
Lyka Labs has 5 GST registrations: 3 active and 2 cancelled or inactive.
Total GSTINs
5
Active
3
Cancelled / inactive
2
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 24AAACL0820G1Z5 | Gujarat | Active | 01 Jul 2017 |
| 27AAACL0820G1ZZ | Maharashtra | Active | 01 Jul 2017 |
| 27AAACL0820G2ZY | Maharashtra | Active | 17 Apr 2018 |
To see the full GST registrations and return filing status of Lyka Labs Limited, buy the company report.
Recent activity
Lyka Labs Limited has 50 board changes on record since 1977: 29 appointments and 21 cessations. The latest: Shailendra Kumar Agrawal was appointed as Company Secretary on 07 Oct 2025.
Filing
Lyka Labs Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Ahmedabad.
Charges
A charge with Others amounted to Rs. 1.00 Cr with Charge ID 101214171 was registered on 16 Dec 2025.
Appointed
Shailendra Kumar Agrawal was appointed as Company Secretary.
Charges
A charge with Yes Bank Limited of Rs. 36.38 Cr registered on 24 Jul 2023 with Charge ID 100756852 was modified on 12 Aug 2025.
Ceased
Dhara Pratik Shah ceased to be Director.
AGM
Lyka Labs Limited last Annual general meeting of members was held on 01 Aug 2025 as per latest MCA records.
Ceased
Shekhar Ramjeet Singh ceased to be Company Secretary.
Appointed
Archana Surendra Yadav was appointed as Director.
Charges
A charge registered on 26 Sep 2024 via Charge ID 100989525 with Others was fully satisfied on 12 Mar 2025.
Appointed
Shekhar Ramjeet Singh was appointed as Company Secretary.
Charges
A charge with Others amounted to Rs. 2.34 Cr with Charge ID 100989525 was registered on 26 Sep 2024.
Appointed
Neeraj Golas was appointed as Director.
173 earlier events are in the company report.
News
Frequently asked questions
Lyka Labs is an active public limited company based in Ankleshwar, Gujarat, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 29 December 1976 (50+ years old) and is registered under CIN L24230GJ1976PLC008738. Listed on BSE: 500259 and NSE: LYKALABS.
Lyka Labs reported revenue of ₹128.44 Cr for FY 2025-26 (down 7.3% YoY) based on consolidated financials.
Lyka Labs has 7 current directors:
- Kunal Narendra Gandhi - Managing Director
- Prashant Godha - Director
- Babu Lal Jain - Director
- Shashil Philip Mendonsa - Director
- Yogesh Babulal Shah - Director
- Archana Surendra Yadav - Director
- Neeraj Golas - Director
The latest financial statements of Lyka Labs on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 01 August 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Lyka Labs is 24AAACL0820G1Z5, registered in Gujarat. The company has 5 GST registrations in all, of which 3 are active and 2 are cancelled or inactive. Other active GSTINs include 27AAACL0820G1ZZ (Maharashtra), 27AAACL0820G2ZY (Maharashtra).
The CIN (Corporate Identification Number) of Lyka Labs is L24230GJ1976PLC008738. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Lyka Labs is a listed company as per MCA records. Its shares are listed on both BSE (code: 500259) and NSE (symbol: LYKALABS).
Lyka Labs has 249 court cases on record: 94 filed by the company and 155 filed against it. 55 are pending. Most are in the district courts.
Lyka Labs was incorporated on 29 December 1976, making it 50+ years old. It is registered with the Registrar of Companies, Ahmedabad.
Lyka Labs has 153 deals on record (145 market trades, 3 funding rounds, 3 secondary share transfers), with disclosed funding of ₹120.13 Cr; the latest was in September 2024.
The peers of Lyka Labs by revenue are Alventa Pharma Limited, Apotex Pharmachem India Private Limited, Sovereign Pharma Private Limited, Svizera Labs Private Limited, Ratnatris Pharmaceuticals Private Limited and 4 more, all in the Pharma industry (API Manufacturers, Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Shailendra Kumar Agrawal was appointed as Company Secretary on 07 Oct 2025. Dhara Pratik Shah ceased to be Director on 03 Aug 2025. Shekhar Ramjeet Singh ceased to be Company Secretary on 01 Aug 2025. Lyka Labs has 50 board changes on record in total.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages